Global Oral GLP-1 Agonists Market Size Likely to Grow at a CAGR of 12.25% By 2035

It is estimated that the global oral GLP-1 agonists market will be valued at approximately USD 65.15 billion in 2025, rising to around USD 72.87 billion in 2026, and is expected to reach close to USD 206.83 billion by 2035, expanding at a CAGR of 12.25% during the forecast period from 2026 to 2035.

Oral GLP-1 Agonists market  Revenue and Trends

The demand in the market for Oral GLP-1 Agonists is also high and steady on the background of its vast application and favorable preference among different age groups owing to its safety and efficiency against pain and fever. The prevalence of cold, flu and infections is observed to rise with higher population's inclination toward health and ease of procuring Over The Counter products boosting market growth. The increasing penetration in health care services along with rising global population and demand for paracetamol for patient care in hospitals and home settings are also major demand generators, and emerging new manufacturing methods, increased production in developing countries and growing importance of cheaper treatments promises an increasing long term market growth.

What are the main growth drivers of Oral GLP-1 Agonists market?

The Oral GLP-1 Agonists market is growing owing to increasing prevalence of type 2 diabetes and obesity, coupled with growing demand for oral treatment options that increase efficacy and treatment compliance with sustained benefits and ease of administration in patients. The increasing trend toward managing metabolic disorders at an early stage, enhanced health awareness, expanded healthcare access, and the widespread prescription of oral GLP-1 drugs in varied patient population due to ease of use are all factors propelling market growth. Rising health expenditure, increasing global population, and requirement of convenient alternative to injectable dosage forms also act as market growth factors.

Moreover, innovation in products like improved oral drug delivery and optimized formulations for better bioavailability and improved treatment outcome are further leading to increased convenience and improved efficacy of treatments thus increasing demand for such products. The increased drug manufacturing capability, robust R&D pipelines, strategic partnerships amongst major industry players and support from government towards effective diabetes treatment, established distribution channels and need for safe and effective and sustained metabolic disease management is all contributing to market growth in the upcoming forecast period.

Segment Insight

By Product

Semaglutide has the largest share in the Oral GLP-1 Agonists market due to high clinical efficacy (blood glucose levels and weight management) and availability of oral formulation. Tirzepatide is the fastest growing product owing to dual agonist mechanism and better response in Type 2 Diabetes Mellitus and obesity. Dulaglutide and Liraglutide retain a significant market share due to long term usage and efficacy. Other products are expected to register a steady growth over the coming years with development and pipeline expansion.

By Application

Type 2 Diabetes Mellitus is dominating the market owing to high prevalence and high efficiency of GLP-1 agonists for blood glucose management. Obesity and Chronic Weight Management segment is growing at a rapid pace due to the increase in popularity for weight loss and increase in awareness about metabolic health. Cardiovascular Risk segment is expected to witness a steady growth owing to the decrease in cardiovascular risk and event outcomes due to GLP-1 therapies.

By Route of Administration

Oral segment is witnessing significant traction owing to increasing preference for non-invasive delivery mode, and improved compliance with oral formulation over the injection form. Injectable/ parenteral form still accounts for a major chunk due to high efficacy and bioavailability, however, oral segment is gaining market share at a high pace and is expected to grow further with the enhancement in technology.

By Region

North America accounts for the largest share in the Oral GLP-1 Agonists market owing to advanced healthcare infrastructure and high adoption of novel therapies. Europe also represents a major portion in the market share due to strict regulations and increasing health initiatives for managing chronic diseases. The Asia-Pacific region is expected to witness the highest growth rate due to rise in incidences of Diabetes Mellitus and Obesity coupled with high growth in healthcare and increased awareness from developing countries such as China and India. The Middle East & Africa and Latin America are projected to show a steady growth rate over the forecast period with enhanced infrastructure and growing the inclination towards advanced medical therapies.

Report Scope

Recent Developments

• In February 2024, Johnson & Johnson revealed strategic advancements in the Oral GLP-1 Agonists market. In order to consolidate their portfolio in metabolic disease they plan to invest in research partnerships, optimize their oral drug delivery methods and further extend their supply chain. Demand for effective and accessible treatments for diseases like type 2 diabetes mellitus and obesity continue to grow.

List of the prominent players in the Oral GLP-1 Agonists Market:

• Novo Nordisk A/S

• Eli Lilly and Company

• Pfizer Inc.

• AstraZeneca plc

• Sanofi S.A.

• Roche Holding AG

• Merck & Co. Inc.

• Boehringer Ingelheim International GmbH

• Johnson & Johnson

• Amgen Inc.

• Structure Therapeutics Inc.

• Viking Therapeutics Inc.

• Altimmune, Inc.

• Zealand Pharma A/S

• Hanmi Pharmaceutical Co. Ltd.

• Others

The Oral GLP-1 Agonists Market is segmented as follows:

By Product

• Semaglutide

• Tirzepatide

• Dulaglutide

• Liraglutide

• Others

By Application

• Type 2 Diabetes Mellitus

• Obesity / Chronic Weight Management

• Cardiovascular Risk

By Route of Administration

• Injectable / Parenteral

• Oral

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America